News Chart Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-12 EDT			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

c6d69fc5f96f761c3d09.M9BTvRMJjFZy3x4Ojg3M5cIWasfPRzGgjDV9wzWUtPc.BZ8Gz2M44xwn63lUw1Wu16NiCK38DwP1vwEugV725MResxnnJDrFFDvsdQ~0411ad8569b3079f1866a90e7079b31c